Development of a diagnostic nomogram for alpha-fetoprotein-negative hepatocellular carcinoma based on serological biomarkers

doi:10.4251/wjgo.v16.i6.2463

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (683)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

HTML

478

Figures (1-6)

Tables (1-4)

Sum=610

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=60

Jun 15, 2024 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2463-2475
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2463

Table 1 Baseline characteristics of the study population, n (%)

	HCC (n = 180)	Healthy (n = 100)	F/χ²/Z value	P value
Demographics
Age, yr, mean (SD), gender	52.46 (9.18)	49.79 (8.26)	2.318	0.129
Male	165 (91.7)	85 (85)	2.987	0.084
Female	15 (8.3)	15 (15)	2.987	0.084
LFTs
AST (U/L), median (IQR)	47 (33, 76.75)	20 (16, 25)	-11.534	< 0.001
ALT (U/L), median (IQR)	38 (26, 59.75)	21 (18, 25.75)	-9.764	< 0.001
GGT (U/L), median (IQR)	86 (45, 147)	26 (20, 36)	-9.744	< 0.001
ALP (U/L), median (IQR)	100.5 (67.25, 149)	62 (53, 78)	-7.354	< 0.001
HCC biomarkers
AFP (U/L) median (IQR)	25 (7.49, 572.6)	4 (3, 5)	-11.269	< 0.001
GP73 (ng/mL) median (IQR)	147.5 (111, 217.5)	54 (45, 73.75)	-11.775	< 0.001
DCP (ng/mL) median (IQR)	10 (7, 513)	6 (2.25, 8)	-8.172	< 0.001
CK18-M65 (U/L) median (IQR)	802 (469.5, 1769)	119 (94, 194.5)	-12.536	< 0.001
CK18-M30 (U/L) median (IQR)	407.5 (219, 890.75)	99 (80, 144)	-10.572	< 0.001

HCC: Hepatocellular carcinoma; AST: Aspartate transaminase; ALT: Alanine transaminase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; LFTs: Liver function tests; DCP: Des-γ-carboxyprothrombin.

Citation: He L, Zhang C, Liu LL, Huang LP, Lu WJ, Zhang YY, Zou DY, Wang YF, Zhang Q, Yang XL. Development of a diagnostic nomogram for alpha-fetoprotein-negative hepatocellular carcinoma based on serological biomarkers. World J Gastrointest Oncol 2024; 16(6): 2463-2475
URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2463.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i6.2463